Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Oxlumo (lumasiran) is a small interfering RNA (siRNA) therapeutic, the first approved treatment specifically for primary hyperoxaluria type 1 (PH1), a rare genetic disorder that causes toxic oxalate buildup and progressive kidney damage.
Oxlumo is FDA-approved to lower urinary and plasma oxalate levels in pediatric and adult patients with primary hyperoxaluria type 1.
Lumasiran works by silencing the HAO1 gene in the liver, reducing production of glycolate oxidase, an enzyme in the oxalate production pathway. This lowers the substrate available for oxalate synthesis, reducing oxalate levels in urine and plasma.
Oxlumo is given by subcutaneous injection, with body-weight-based loading doses followed by less frequent maintenance dosing, as determined by the treating nephrologist or metabolic specialist.
Oxlumo is generally well tolerated, but patients should be aware of the following considerations.
The most common adverse reaction, occurring in a significant proportion of patients. Reactions are usually mild to moderate and self-limiting.
Regular monitoring of urinary and plasma oxalate levels is recommended to assess treatment response.
Oxlumo should be administered by a healthcare professional trained in subcutaneous injection technique, particularly for the initial doses.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Oxlumo (lumasiran) received FDA approval in 2020 and is manufactured by Alnylam Pharmaceuticals, the first approved therapy specifically targeting primary hyperoxaluria type 1.
Import of Oxlumo through a Named Patient Program requires a valid prescription from the treating nephrologist or metabolic specialist, confirmation of PH1 diagnosis (typically via genetic testing), and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Oxlumo directly from Alnylam's authorized supply chain to ensure product authenticity and regulatory compliance.
Oxlumo is sourced through verified, GDP-compliant channels from Alnylam's authorized supply chain to ensure authenticity and quality.
Oxlumo should be stored at 2°C to 25°C (36°F to 77°F), protected from light, and kept in its original carton until time of use.
Once sourced, Oxlumo is packed and transported under appropriate temperature-controlled conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Oxlumo through NPP's regulated import pathway, with nephrology and metabolic disease specialists in major cities supporting the treatment process.
Leading nephrology centers in Mumbai support PH1 diagnosis and treatment coordination for Oxlumo access.
Delhi's major hospitals assist patients with genetic testing and prescription support for Oxlumo.
Bangalore's specialist network offers access to PH1 diagnosis and treatment planning for eligible patients.
Chennai-based specialists coordinate Oxlumo access alongside comprehensive kidney care.
Hyderabad's care institutions support patients pursuing Oxlumo therapy following confirmed PH1 diagnosis.
Kolkata's specialist centers help coordinate documentation and treatment access for Oxlumo.
Pune-based nephrologists assist with diagnosis confirmation and Oxlumo treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Oxlumo.
Kochi's nephrology units assist patients with the documentation needed for Oxlumo access.
Chandigarh's care centers support Oxlumo treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Oxlumo access process.
Lucknow-based centers assist patients pursuing Oxlumo therapy.
Bhubaneswar's institutions support access to Oxlumo for eligible patients.
Guwahati's specialists help coordinate Oxlumo access for patients across the Northeast.
Patients in other cities across India can also access Oxlumo through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
